Monotherapy targeting of BCL-XL has modest effects in solid tumors; however, combinations of BCL-XL with gemcitabine and nab-paclitaxel or MEK inhibition have been reported to enhance PDAC anti-tumor efficacy27,28. This evidence concerns the gene BCL2L1 and neoplasm.